ImmunityBio ends the week with its two most persistent tensions unchanged: a short base that refuses to budge and a small analyst community that keeps its buy ratings firmly in place, with a November earnings date now 37 days away.
Short interest remains the defining feature of this stock. At 12.7% of the free float, roughly 125 million shares, the position has barely moved in either direction, down just 0.05% on the week and 2.5% over the past month. The ORTEX short score holds at 83, placing IBRX in the second percentile of the entire universe on short score rank. Days to cover stand at 15.86 per the most recent FINRA settlement, reflecting how anchored this short base has become. Bears are neither running for the exit nor pressing the position harder. The stock fell 4.95% on the week but bounced 3.6% on Tuesday, leaving the picture roughly where it started.
Borrow conditions have shifted since the earlier note published the same day, and the direction is worth flagging. Availability has continued to drift higher, reaching 17.9% on Tuesday versus roughly 9% in mid-September and a near-zero extreme on August 24 when every share in the lending pool was out. That easing matters because it removes one of the mechanical triggers for a short squeeze: with more shares available to borrow, new shorts can enter more easily. Cost to borrow has also fallen sharply, down 16.6% on the week and 55% over the past month, now running just above 1%, a rate that carries little urgency for anyone holding a short position. The borrow market is still tight by any normal standard, but the direction of travel in September has been toward looser, not tighter.
The analyst picture is uniformly bullish but notably quiet. All three covering firms maintain buy ratings, with targets ranging from $12 at BTIG to $23 at D. Boral Capital against a current price of $8.83. The consensus data is 65 days old, and no firm has moved a target or rating since June. The mean target of $12.75 implies roughly 44% upside from here, but the absence of any fresh action suggests the Street is in a holding pattern ahead of the next catalyst. The bull case rests on ANKTIVA's commercialization in bladder cancer and its potential in further indications. The bear case centres on execution risk in those new indications, regulatory uncertainty, and an ongoing loss profile reflected in a deeply negative earnings yield and a PE ratio of negative 27. The EPS surprise factor score ranks in the 94th percentile, a sign the company has been beating lowered estimates, though near-term EPS momentum scores of 9 and 19 out of 100 signal that forward estimates are still trending down.
Ownership is dominated by the founder. Patrick Soon-Shiong filed a Schedule 13D/A on August 6, disclosing a 64.8% stake, down from 66.3% previously, across his personal holdings and affiliated entities including California Capital Equity and NantWorks. ORTEX flags this as an active 13D filing, meaning Soon-Shiong has declared activist intent. With more than 60% of shares controlled by one investor and a further 9% held by affiliated vehicles, the effective free float is considerably smaller than the headline share count implies, which amplifies the significance of the 12.7% short interest figure. Among institutional buyers, BlackRock added 7.7 million shares as of August and State Street added 3.7 million, modest positions against the founder's dominant stake. Insider activity in the most recent window was limited to option exercises and prearranged 10b5-1 plan sales by two directors in late June and early July, all conducted under pre-set plans and carrying little discretionary signal.
Retail attention has picked up. The ORTEX alt data layer shows a Wikipedia-based attention z-score of 1.91 as of September 22, above average for IBRX's own recent history, consistent with the stock's 347% year-to-date gain drawing fresh interest. This is an attention measure, not a revenue or clinical indicator. The next earnings print is scheduled for November 6, and with the borrow market loosening, short interest unmoved, and analysts sitting on unchanged targets, what happens between now and that date, on ANKTIVA volumes or any new indication data, is the variable the market is waiting on.
See the live data behind this article on ORTEX.
Open IBRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
